VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy 2022 | UCARTCS1: a novel allogeneic CAR-T therapy for myeloma

Roman Galetto, PhD, Cellectis, Paris, France, briefly discusses UCARTCS1, a novel allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developed for the treatment of multiple myeloma. Dr Galetto also highlights the challenges associated with developing CAR-T products that target CS1, and the benefits of using this novel approach for the treatment of myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Cellectis employee

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter